FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology, specifically to an antisense oligonucleotide, and can be used in medicine. Invention discloses an antisense oligonucleotide with modified nucleosides in the composition, which is able to reduce expression of tau protein in a target cell and, as a result, to regulate the functioning of neurons, in particular to influence axon transport in said cells.
EFFECT: present invention can be used in the composition of a drug in the treatment of a number of neurodegenerative diseases, namely Alzheimer's disease (AD), progressive supranuclear paralysis (PSP), frontotemporal dementia (FTD) or FTD with chromosome 17-associated parkinsonism (FTDP-17).
14 cl, 8 ex, 13 tbl, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS FOR MODULATION OF ATAXIN 2 EXPRESSION | 2015 |
|
RU2702838C2 |
| MODULATING EXPRESSION OF ANGIOPOIETIN-LIKE PROTEIN 3 | 2014 |
|
RU2706964C2 |
| COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF DYSTROPHIC MIOTONIN-PROTEINKINASE (DMPK) | 2014 |
|
RU2690333C2 |
| MODULATORS OF COMPLEMENT FACTOR B | 2014 |
|
RU2662967C2 |
| COMPOSITIONS FOR MODULATING EXPRESSION OF SOD-1 | 2015 |
|
RU2704619C2 |
| MODULATION OF ANDROGEN RECEPTOR EXPRESSION | 2013 |
|
RU2670486C9 |
| MODULATION OF THE EXPRESSION OF APOLIPOPROTEIN C-III (APOSIII) IN THE PATIENTS WITH LIPODYSTROPHY | 2016 |
|
RU2737719C2 |
| MODULATION OF FACTOR 11 EXPRESSION | 2014 |
|
RU2739594C2 |
| FACTOR 11 EXPRESSION MODULATION | 2009 |
|
RU2535964C2 |
| NUCLEIC ACID MOLECULES FOR REDUCING THE LEVEL OF PAPD5 OR PAPD7 MRNA FOR TREATING INFECTIOUS HEPATITIS B | 2017 |
|
RU2768699C2 |
